Literature DB >> 22071890

ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Franck Bourdeaut1, Sandrine Ferrand, Laurence Brugières, Marjorie Hilbert, Agnès Ribeiro, Ludovic Lacroix, Jean Bénard, Valérie Combaret, Jean Michon, Dominique Valteau-Couanet, Bertrand Isidor, Xavier Rialland, Maryline Poirée, Anne-Sophie Defachelles, Michel Peuchmaur, Gudrun Schleiermacher, Gaëlle Pierron, Marion Gauthier-Villars, Isabelle Janoueix-Lerosey, Olivier Delattre.   

Abstract

Neuroblastic tumours may occur in a predisposition context. Two main genes are involved: PHOX2B, observed in familial cases and frequently associated with other neurocristopathies (Ondine's and Hirschsprung's disease); and ALK, mostly in familial tumours. We have assessed the frequency of mutations of these two genes in patients with a presumable higher risk of predisposition. We sequenced both genes in 26 perinatal cases (prebirth and <1 month of age, among which 10 were multifocal), 16 multifocal postnatal (>1 month) cases, 3 pairs of affected relatives and 8 patients with multiple malignancies. The whole coding sequences of the two genes were analysed in tumour and/or constitutional DNAs. We found three ALK germline mutations, all in a context of multifocal tumours. Two mutations (T1151R and R1192P) were inherited and shared by several unaffected patients, thus illustrating an incomplete penetrance. Younger age at tumour onset did not seem to offer a relevant selection criterion for ALK analyses. Conversely, multifocal tumours might be the most to benefit from the genetic screening. Finally, no PHOX2B germline mutation was found in this series. In conclusion, ALK deleterious mutations are rare events in patients with a high probability of predisposition. Other predisposing genes remain to be discovered.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071890      PMCID: PMC3283184          DOI: 10.1038/ejhg.2011.195

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  29 in total

1.  Germline PHOX2B mutation in hereditary neuroblastoma.

Authors:  Yael P Mosse; Marci Laudenslager; Deepa Khazi; Alex J Carlisle; Cynthia L Winter; Eric Rappaport; John M Maris
Journal:  Am J Hum Genet       Date:  2004-10       Impact factor: 11.025

2.  Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects.

Authors:  Michael R DeBaun; Emily L Niemitz; D Elizabeth McNeil; Sheri A Brandenburg; Maxwell P Lee; Andrew P Feinberg
Journal:  Am J Hum Genet       Date:  2002-01-28       Impact factor: 11.025

3.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome.

Authors:  F P Li; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1969-12       Impact factor: 13.506

4.  Mutation and cancer: neuroblastoma and pheochromocytoma.

Authors:  A G Knudson; L C Strong
Journal:  Am J Hum Genet       Date:  1972-09       Impact factor: 11.025

5.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

6.  Familial neuroblastoma. Case reports, literature review, and etiologic considerations.

Authors:  B H Kushner; F Gilbert; L Helson
Journal:  Cancer       Date:  1986-05-01       Impact factor: 6.860

7.  Hirschsprung's disease, Ondine's curse, and neuroblastoma--manifestations of neurocristopathy.

Authors:  J E Roshkow; J O Haller; W E Berdon; S M Sane
Journal:  Pediatr Radiol       Date:  1988

8.  Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.

Authors:  Delphine Trochet; Franck Bourdeaut; Isabelle Janoueix-Lerosey; Anne Deville; Loïc de Pontual; Gudrun Schleiermacher; Carole Coze; Nicole Philip; Thierry Frébourg; Arnold Munnich; Stanislas Lyonnet; Olivier Delattre; Jeanne Amiel
Journal:  Am J Hum Genet       Date:  2004-03-11       Impact factor: 11.025

9.  Prevalence and functional consequence of PHOX2B mutations in neuroblastoma.

Authors:  E H Raabe; M Laudenslager; C Winter; N Wasserman; K Cole; M LaQuaglia; D J Maris; Y P Mosse; J M Maris
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

10.  PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset Central Hypoventilation syndrome.

Authors:  I Matera; T Bachetti; F Puppo; M Di Duca; F Morandi; G M Casiraghi; M R Cilio; R Hennekam; R Hofstra; J G Schöber; R Ravazzolo; G Ottonello; I Ceccherini
Journal:  J Med Genet       Date:  2004-05       Impact factor: 6.318

View more
  14 in total

Review 1.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

Review 2.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

3.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Authors:  Scott C Bresler; Daniel A Weiser; Peter J Huwe; Jin H Park; Kateryna Krytska; Hannah Ryles; Marci Laudenslager; Eric F Rappaport; Andrew C Wood; Patrick W McGrady; Michael D Hogarty; Wendy B London; Ravi Radhakrishnan; Mark A Lemmon; Yaël P Mossé
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

Review 4.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 5.  Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Authors:  Laura E Ritenour; Michael P Randall; Kristopher R Bosse; Sharon J Diskin
Journal:  Cell Tissue Res       Date:  2018-03-27       Impact factor: 5.249

Review 6.  Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Authors:  Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

7.  High-resolution array CGH profiling identifies Na/K transporting ATPase interacting 2 (NKAIN2) as a predisposing candidate gene in neuroblastoma.

Authors:  Paolo Romania; Aurora Castellano; Cecilia Surace; Arianna Citti; Maria Antonietta De Ioris; Pietro Sirleto; Marilena De Mariano; Luca Longo; Renata Boldrini; Adriano Angioni; Franco Locatelli; Doriana Fruci
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

8.  Genetics of Bladder Malignant Tumors in Childhood.

Authors:  Andrea Zangari; Johan Zaini; Caterina Gulìa
Journal:  Curr Genomics       Date:  2016-02       Impact factor: 2.236

9.  Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.

Authors:  Alex Cazes; Lucille Lopez-Delisle; Konstantina Tsarovina; Cécile Pierre-Eugène; Katleen De Preter; Michel Peuchmaur; André Nicolas; Claire Provost; Caroline Louis-Brennetot; Romain Daveau; Candy Kumps; Ilaria Cascone; Gudrun Schleiermacher; Aurélie Prignon; Frank Speleman; Hermann Rohrer; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Oncotarget       Date:  2014-05-15

10.  TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

Authors:  Amit Dipak Amin; Lingxiao Li; Soumya S Rajan; Vijay Gokhale; Matthew J Groysman; Praechompoo Pongtornpipat; Edgar O Tapia; Mengdie Wang; Jonathan H Schatz
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.